Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

NCT01320020 is registered in ClinicalTrials.gov with Neovii Biotech as lead sponsor.

NCT NCT01320020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01320020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Lead sponsor
Neovii Biotech
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2011
Completion date
March 31, 2013
Enrollment
16 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial cancer patients